---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-24-000162"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2024-09-09T23:59:59+00:00"
generated_at: "2026-05-31T05:55:46.692867+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports 76% response rate in Graves' Disease Phase 2a; IND cleared for IMVT-1402 pivotal trial

## Summary
- High-dose batoclimab (680 mg SC weekly) achieved 76% response rate and 56% ATD-free response at week 12 in patients uncontrolled on antithyroid drugs.
- Lower-dose batoclimab (340 mg) yielded 68% response and 36% ATD-free response; 70%+ IgG reduction linked to nearly 3x higher ATD-free response.
- FDA IND cleared; pivotal trial of IMVT-1402 in Graves' Disease expected to initiate by December 31, 2024.
- Real-world claims data indicate 25–30% of GD patients per year are uncontrolled on ATDs with limited existing therapeutic options.

## SEC filing metadata
- accession: 0001764013-24-000162
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2024-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000162/0001764013-24-000162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000162/imvt-20240909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-24-000162
- JSON: https://secwatch.observer/filing/0001764013-24-000162.json
- Plain text: https://secwatch.observer/filing/0001764013-24-000162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.